


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:


Claims 1-11 (cancelled)

Claim 12 (new): A method for alleviating retinoid induced skin injury comprising administering an effective amount of an erb inhibitor to a patient in need thereof.

Claim 13 (new): A method according to claim 12 in which said erb inhibitor is a compound represented by the formula





wherein Q is






p is 0 or 1;

X is -D-E-F and Y is -SR⁴, -OR⁴, -NHR³, or hydrogen, or X is -SR⁴, -OR⁴, -NHR³, or hydrogen, and Y is -D-E-F;





or absent;



R¹ is hydrogen, halogen, or C₁-C₆ alkyl;

R², R³, and R⁴ are independently hydrogen, C₁-C₆ alkyl, -(CH₂)_n-N-piperidinyl, -(CH₂)_n-N-piperazinyl, -(CH₂)_n-N₁-piperazinyl[N₄-(C₁-C₆)alkyl], -(CH₂)_n-N-pyrrolidyl, -(CH₂)_n-pyridinyl, -(CH₂)_n-N-imidazolyl, -(CH₂)_n-imidazolyl, -(CH₂)_n-N-morpholino, -(CH₂)_n-N-thiomorpholino, -(CH₂)_n-N-hexahydroazepine or substituted C₁-C₆ alkyl, wherein the

A
|

substituents are selected from OH, -NH₂, or -N-B, A and B are independently hydrogen, C₁-C₆ alkyl, -(CH₂)_nOH, -(CH₂)_n-N-piperidinyl, -(CH₂)_n-N-piperazinyl, -(CH₂)_n-N₁-piperazinyl[N₄-(C₁-C₆)alkyl], -(CH₂)_n-N-pyrrolidyl, -(CH₂)_n-N-pyridyl, -(CH₂)_n-imidazolyl, or -(CH₂)_n-N-imidazolyl;

E¹, E², and E³ are independently halogen, C₁-C₆ alkyl, C₃-C₈ cycloalkyl, C₁-C₆ alkoxy, C₃-C₈ cycloalkoxy, nitro, C₁-C₆ perfluoroalkyl, hydroxy,

C₁-C₆ acyloxy, -NH₂, -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂,
 -NH(C₃-C₈ cycloalkyl), -N(C₃-C₈ cycloalkyl)₂, hydroxymethyl,
 C₁-C₆ acyl, cyano, azido, C₁-C₆ thioalkyl, C₁-C₆ sulfinylalkyl,
 C₁-C₆ sulfonylalkyl, C₃-C₈ thiocycloalkyl, C₃-C₈ sulfinylcycloalkyl,
 C₃-C₈ sulfonylcycloalkyl, mercapto, C₁-C₆ alkoxycarbonyl,
 C₃-C₈ cycloalkoxycarbonyl, C₂-C₄ alkenyl, C₄-C₈ cycloalkenyl, or
 C₂-C₄ alkynyl;

R⁵ is hydrogen, halogen, C₁-C₆-perfluoroalkyl, 1,1-difluoro(C₁-C₆)alkyl,
 C₁-C₆ alkyl, -(CH₂)_n-N-piperidiny, -(CH₂)_n-piperaziny, -(CH₂)_n-
 piperaziny[N₄-(C₁-C₆)alkyl], -(CH₂)_n-N-pyrrolidyl, -(CH₂)_n-pyridinyl,
 -(CH₂)_n-N-imidazolyl, -(CH₂)_n-N-morpholino,
 -(CH₂)_n-N-thiomorpholino, -C=CH₂, -CH=CH-(C₁-C₆)alkyl,


|
H

-(CH₂)_n-N-hexahydroazepine, -(CH₂)_nNH₂, -(CH₂)_nNH(C₁-C₆alkyl),
 -(CH₂)_nN(C₁-C₆ alkyl)₂, -1-oxo(C₁-C₆)alkyl, carboxy, (C₁-C₆)
 alkyloxycarbonyl, N-(C₁-C₆)alkylcarbonyl, phenyl or substituted
 phenyl, wherein the substituted phenyl can have from one to three
 substituents independently selected from Z¹, Z², Z³ or a monocyclic
 heteroaryl group, and each C₁-C₆ alkyl group can be substituted with
 -OH, -NH₂ or -NAB, where A and B are as defined above, R⁶ is
 hydrogen or C₁-C₆ alkyl; and


n is 1 to 4, p is 0 and 1, and the pharmaceutically acceptable salts, esters,
 amides, and prodrugs thereof.

Claim 14 (new): A method according to claim 13 wherein the erb inhibitor is
 5-(4-methyl-piperazin-1-yl)-pent-2-ynoic acid [4-(3-chloro-4-fluoro-
 phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-amide or N⁴-(3-bromo-
 phenyl)-N⁶-methyl-pyrido[3,4-d]pyrimidine-4,6-diamine.



Claim 15 (new): A method according to Claim 12 wherein said erb inhibitor is a
 compound represented by the Formula




wherein X is -D-E-F and Y is -SR⁴, halogen, -OR⁴, -NHR³, or hydrogen,
or X is -SR⁴, halogen, -OR⁴, -NHR³, or hydrogen, and Y is -D-E-F;



or absent;



provided that when E is $\begin{array}{c} \text{O} \\ || \\ -\text{S}- \end{array}$ or $\begin{array}{c} \text{O} \\ || \\ -\text{S}- \\ || \\ \text{O} \end{array}$, D is not



R¹ is hydrogen, halogen, or C₁-C₆ alkyl;

R², R³, and R⁴ are independently hydrogen, C₁-C₆ alkyl,

-(CH₂)_n-N-piperidinyl, -(CH₂)_n-N-piperazinyl,

-(CH₂)_n-N₁-piperazinyl[N₄-(C₁-C₆)alkyl], -(CH₂)_n-N-pyrrolidyl,

-(CH₂)_n-pyridinyl, -(CH₂)_n-N-imidazolyl, -(CH₂)_n-imidazolyl,

-(CH₂)_n-N-morpholino, -(CH₂)_n-N-thiomorpholino,

-(CH₂)_n-N-hexahydroazepine or substituted C₁-C₆ alkyl, wherein



the substituents are selected from -OH, -NH₂, or -N-B, A and B are

independently hydrogen, C₁-C₆ alkyl, -(CH₂)_nOH, -(CH₂)_n-N-piperidinyl,

-(CH₂)_n-N-piperazinyl, -(CH₂)_n-N₁-piperazinyl[N₄-(C₁-C₆-)alkyl],

-(CH₂)_n-N-pyrrolidyl, -(CH₂)_n-N-pyridyl, -(CH₂)_n-imidazolyl,

or -(CH₂)_n-N-imidazolyl;

Z¹, Z², or Z³ are independently hydrogen, halogen, C₁-C₆ alkyl,

C₃-C₈ cycloalkyl, C₁-C₆ alkoxy, C₃-C₈ cycloalkoxy, nitro,

C₁-C₆ perfluoroalkyl, hydroxy, C₁-C₆ acyloxy, -NH₂,

-NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, -NH(C₃-C₈ cycloalkyl),

-N(C₃-C₈ cycloalkyl)₂, hydroxymethyl, C₁-C₆ acyl, cyano, azido,

C₁-C₆ thioalkyl, C₁-C₆ sulfinylalkyl, C₁-C₆ sulfonylalkyl,

C₃-C₈ thiocycloalkyl, C₃-C₈ sulfinylcycloalkyl,

C₃-C₈ sulfonylcycloalkyl, mercapto, C₁-C₆ alkoxycarbonyl,

C₃-C₈ cycloalkoxycarbonyl, C₂-C₄ alkenyl, C₄-C₈ cycloalkenyl, or

C₂-C₄ alkynyl;

R⁵ is hydrogen, halogen, C₁-C₆-perfluoroalkyl, 1,1-difluoro(C₁-C₆)alkyl,

C₁-C₆alkyl, -(CH₂)_n-N-piperidinyl, -(CH₂)_n-piperazinyl, -(CH₂)_n-

piperazinyl[N₄-(C₁-C₆)alkyl], -(CH₂)_n-N-pyrrolidyl,

-(CH₂)_n-pyridinyl, -(CH₂)_n-N-imidazolyl, -(CH₂)_n-N-morpholino,

-(CH₂)_n-N-thiomorpholino, G=CH₂, -CH=CH-(C₁-C₆)alkyl,



-(CH₂)_n-N-hexahydroazepine, -(CH₂)_nNH₂,

-(CH₂)_nNH(C₁-C₆alkyl), -(CH₂)_nN(C₁-C₆alkyl)₂,


-1-oxo(C₁-C₆)alkyl, carboxy, (C₁-C₆)alkyloxycarbonyl,

N-(C₁-C₆)alkylcarbonyl, phenyl or substituted phenyl, wherein the substituted phenyl can have from one to three substituents independently selected from Z¹, Z², Z³ or a monocyclic heteroaryl group, and each C₁-C₆ alkyl group above in R⁵ can be substituted with -OH, -NH₂ or -NAB, where A and B are as defined above, R⁶ is hydrogen or C₁-C₆ alkyl; R¹³ is hydrogen or halogen; and n is 1 to 4, p is 0 or 1, and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof.


Claim 16 (new): A method according to claim 15 wherein said compound is N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide or N-[4-(3-bromo-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide.

Claim 17 (new): A method for alleviating the dermal side effects associated with the topical administration of retinoids comprising the administration of an effective amount of an erb inhibitor to a patient in need thereof.



Claim 18 (new): A method according to claim 17 in which said erb inhibitor is a compound represented by the formula




wherein Q is




X is -D-E-F and Y is -SR⁴, -OR⁴, -NHR³, or hydrogen, or X is -SR⁴, -OR⁴, -NHR³, or hydrogen, and Y is -D-E-F;



E is $\text{—}\overset{\text{O}}{\overset{\parallel}{\text{C}}}\text{—}$, $\text{—}\overset{\text{O}}{\overset{\parallel}{\underset{\text{O}}{\text{S}}}}\text{—}$, $\text{—}\overset{\text{O}}{\overset{\parallel}{\underset{\text{OR}^2}{\text{P}}}}\text{—}$, or $\text{—}\overset{\text{O}}{\overset{\parallel}{\text{S}}}\text{—}$;



provided that when E is -S- or -S-, D is not



R¹ is hydrogen, halogen, or C₁-C₆ alkyl;

R², R³, and R⁴ are independently hydrogen, C₁-C₆ alkyl, -(CH₂)_n-N-piperidinyl, -(CH₂)_n-N-piperazinyl, -(CH₂)_n-N₁-piperazinyl[N₄-(C₁-C₆)alkyl], -(CH₂)_n-N-pyrrolidyl, -(CH₂)_n-pyridinyl, -(CH₂)_n-N-imidazolyl, -(CH₂)_n-imidazolyl, -(CH₂)_n-N-morpholino, -(CH₂)_n-N-thiomorpholino, -(CH₂)_n-N-hexahydroazepine or substituted C₁-C₆ alkyl, wherein the

A
|

substituents are selected from OH, -NH₂, or -N-B, A and B are independently hydrogen, C₁-C₆ alkyl, -(CH₂)_nOH, -(CH₂)_n-N-piperidinyl, -(CH₂)_n-N-piperazinyl, -(CH₂)_n-N₁-piperazinyl[N₄-(C₁-C₆)alkyl], -(CH₂)_n-N-pyrrolidyl, -(CH₂)_n-N-pyridyl, -(CH₂)_n-imidazolyl, or -(CH₂)_n-N-imidazolyl;

E¹, E², and E³ are independently halogen, C₁-C₆ alkyl, C₃-C₈ cycloalkyl, C₁-C₆ alkoxy, C₃-C₈ cycloalkoxy, nitro, C₁-C₆ perfluoroalkyl, hydroxy, C₁-C₆ acyloxy, -NH₂, -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, -NH(C₃-C₈ cycloalkyl), -N(C₃-C₈ cycloalkyl)₂, hydroxymethyl, C₁-C₆ acyl, cyano, azido, C₁-C₆ thioalkyl, C₁-C₆ sulfinylalkyl, C₁-C₆ sulfonylalkyl, C₃-C₈ thiocycloalkyl, C₃-C₈ sulfinylcycloalkyl, C₃-C₈ sulfonylcycloalkyl, mercapto, C₁-C₆ alkoxycarbonyl, C₃-C₈ cycloalkoxycarbonyl, C₂-C₄ alkenyl, C₄-C₈ cycloalkenyl, or C₂-C₄ alkynyl;

R⁵ is hydrogen, halogen, C₁-C₆-perfluoroalkyl, 1,1-difluoro(C₁-C₆)alkyl, C₁-C₆ alkyl, -(CH₂)_n-N-piperidinyl, -(CH₂)_n-piperazinyl, -(CH₂)_n-piperazinyl[N₄-(C₁-C₆)alkyl], -(CH₂)_n-N-pyrrolidyl, -(CH₂)_n-pyridinyl, -(CH₂)_n-N-imidazolyl, -(CH₂)_n-N-morpholino, -(CH₂)_n-N-thiomorpholino, -C=CH₂, -CH=CH-(C₁-C₆)alkyl,


|
H

-(CH₂)_n-N-hexahydroazepine, -(CH₂)_nNH₂, -(CH₂)_nNH(C₁-C₆alkyl), -(CH₂)_nN(C₁-C₆ alkyl)₂, -1-oxo(C₁-C₆)alkyl, carboxy, (C₁-C₆) alkyloxycarbonyl, N-(C₁-C₆)alkylcarbamoyl, phenyl or substituted phenyl, wherein the substituted phenyl can have from one to three substituents independently selected from Z¹, Z², Z³ or a monocyclic heteroaryl group,


and each C₁-C₆ alkyl group can be substituted with -OH, -NH₂ or -NAB, where A and B are as defined above, R⁶ is hydrogen or C₁-C₆ alkyl; and n is 1 to 4, p is 0 and 1, and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof.

Claim 19 (new): A method according to claim 17 wherein the erb inhibitor is 5-(4-methyl-piperazin-1-yl)-pent-2-ynoic acid [4-(3-chloro-4-fluorophenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-amide or N⁴-(3-bromophenyl)-N⁶-methyl-pyrido[3,4-d]pyrimidine-4,6-diamine.



Claim 20 (new): A method according to Claim 17 wherein said erb inhibitor is a compound represented by the Formula




wherein X is -D-E-F and Y is -SR⁴, halogen, -OR⁴, -NHR³, or hydrogen, or X is -SR⁴, halogen, -OR⁴, -NHR³, or hydrogen, and Y is -D-E-F;



or absent;



provided that when E is $\begin{array}{c} \text{O} \quad \text{O} \\ \parallel \quad \parallel \\ -\text{S}- \text{ or } -\text{S}- \end{array}$, D is not



R¹ is hydrogen, halogen, or C₁-C₆ alkyl;

R², R³, and R⁴ are independently hydrogen, C₁-C₆ alkyl, -(CH₂)_n-N-piperidinyl, -(CH₂)_n-N-piperazinyl, -(CH₂)_n-N₁-piperazinyl[N₄-(C₁-C₆)alkyl], -(CH₂)_n-N-pyrrolidyl, -(CH₂)_n-pyridinyl, -(CH₂)_n-N-imidazolyl, -(CH₂)_n-imidazolyl, -(CH₂)_n-N-morpholino, -(CH₂)_n-N-thiomorpholino, -(CH₂)_n-N-hexahydroazepine or substituted C₁-C₆ alkyl, wherein

A
|

the substituents are selected from -OH, -NH₂, or -N-B, A and B are independently hydrogen, C₁-C₆ alkyl, -(CH₂)_nOH, -(CH₂)_n-N-piperidinyl, -(CH₂)_n-N-piperazinyl, -(CH₂)_n-N₁-piperazinyl[N₄-(C₁-C₆-)alkyl], -(CH₂)_n-N-pyrrolidyl, -(CH₂)_n-N-pyridyl, -(CH₂)_n-imidazolyl, or -(CH₂)_n-N-imidazolyl;

Z¹, Z², or Z³ are independently hydrogen, halogen, C₁-C₆ alkyl, C₃-C₈ cycloalkyl, C₁-C₆ alkoxy, C₃-C₈ cycloalkoxy, nitro, C₁-C₆ perfluoroalkyl, hydroxy, C₁-C₆ acyloxy, -NH₂, -NH(C₁-C₆ alkyl), -N(C₁-C₆ alkyl)₂, -NH(C₃-C₈ cycloalkyl), -N(C₃-C₈ cycloalkyl)₂, hydroxymethyl, C₁-C₆ acyl, cyano, azido, C₁-C₆ thioalkyl, C₁-C₆ sulfinylalkyl, C₁-C₆ sulfonylalkyl, C₃-C₈ thiocycloalkyl,

C₃-C₈ sulfinylcycloalkyl, C₃-C₈ sulfonylcycloalkyl, mercapto,
 C₁-C₆ alkoxycarbonyl, C₃-C₈ cycloalkoxycarbonyl, C₂-C₄ alkenyl,
 C₄-C₈ cycloalkenyl, or C₂-C₄ alkynyl;
 R⁵ is hydrogen, halogen, C₁-C₆-perfluoroalkyl, 1,1-difluoro(C₁-C₆)alkyl,
 C₁-C₆alkyl, -(CH₂)_n-N-piperidinyl, -(CH₂)_n-piperazinyl, -(CH₂)_n-
 piperazinyl[N₄-(C₁-C₆)alkyl], -(CH₂)_n-N-pyrrolidyl, -(CH₂)_n-pyridinyl,
 -(CH₂)_n-N-imidazolyl, -(CH₂)_n-N-morpholino,
 -(CH₂)_n-N-thiomorpholino, - $\begin{array}{c} \text{C}=\text{CH}_2 \\ | \\ \text{H} \end{array}$, -CH=CH-(C₁-C₆)alkyl,
 -(CH₂)_n-N-hexahydroazepine, -(CH₂)_nNH₂, -(CH₂)_nNH(C₁-C₆alkyl),
 -(CH₂)_nN(C₁-C₆alkyl)₂, -1-oxo(C₁-C₆)alkyl, carboxy,
 (C₁-C₆)alkyloxycarbonyl, N-(C₁-C₆)alkylcarbamoyl, phenyl or substituted
 phenyl, wherein the substituted phenyl can have from one to three
 substituents independently selected from Z¹, Z², Z³ or a monocyclic
 heteroaryl group, and each C₁-C₆ alkyl group above in R⁵ can be
 substituted with -OH, -NH₂ or -NAB, where A and B are as defined above,
 R⁶ is hydrogen or C₁-C₆ alkyl; R¹³ is hydrogen or halogen; and
 n is 1 to 4, p is 0 or 1, and the pharmaceutically acceptable salts, esters,
 amides, and prodrugs thereof.

Claim 21 (new): A method according to claim 17 wherein said compound is N-[4-
 (3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-
 quinazolin-6-yl]-acrylamide or N-[4-(3-bromo-phenylamino)-7-(3-
 morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide.